0.04
+0.0135(+53.36%)
Currency In USD
| Previous Close | 0.03 |
| Open | 0.04 |
| Day High | 0.04 |
| Day Low | 0.03 |
| 52-Week High | 0.04 |
| 52-Week Low | 0.03 |
| Volume | 3,420 |
| Average Volume | 56,642.88 |
| Market Cap | 17.95M |
| PE | -0.02 |
| EPS | -1.73 |
| Moving Average 50 Days | 0.04 |
| Moving Average 200 Days | 0.05 |
| Change | 0.01 |
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
GlobeNewswire Inc.
May 14, 2025 12:00 PM GMT
Pre-NDA Minutes from April 2, 2025, Meeting Received NDA Submission Planned this Summer KANSAS CITY, Kan., May 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Releas
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
GlobeNewswire Inc.
Apr 29, 2025 12:00 PM GMT
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical c
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
GlobeNewswire Inc.
Apr 09, 2025 12:00 PM GMT
CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide Non-Dilutive Funding Expands Pipeline an